Adenocarcinomas of the esophagogastric junction: experiences at a single institution in China

World Journal of Surgical Oncology

Chengxue Dang¹  Kun Zhu¹  Yongchun Song¹  Yao Cheng¹  Wei Wang¹  Hao Zhang¹ 

[1] The Department of Surgical Oncology, College of Medicine, The First Affiliated Hospital, Xi’an Jiaotong University, 277 W. Yanta Road, Xi’an, Shaanxi, 710061 China

关键词: Prognosis;    Resection;    Adenocarcinoma of the esophagogastric junction;   

Others  :  823713
DOI  :  10.1186/1477-7819-11-155

 received in 2012-12-31, accepted in 2013-07-07,  发布年份 2013

【 摘 要 】

Background

The incidence of adenocarcinoma of the esophagogastric junction is increasing. This study aims to evaluate the clinicopathological features of Chinese patients with adenocarcinoma of the esophagogastric junction and to define prognostic factors.

Methods

We retrospectively reviewed a database of 382 consecutive patients with adenocarcinoma of the esophagogastric junction at the First Affiliated Hospital of Xi’an Jiaotong University from January 2005 to March 2010. All patients were classified according to the Siewert’s classification and staged according to the latest edition of the American Joint Committee on Cancer categories.

Results

Six of the 382 patients had type I adenocarcinoma, 220 had type II, and 156 had type III. There was no significant difference in the overall survival of different Siewert subtypes. According to the multivariate analysis, pathological lymph node stage, age, and the existence of lymphovascular invasion were the independent factors of prognosis of adenocarcinoma of the esophagogastric junction following surgery.

Conclusions

On the data, the distribution of the three types of tumor was found to be different from that reported in Western countries. Lymph node metastasis, lymphovascular invasion, and age were significant and independent factors for poor prognosis after R0 resection for adenocarcinoma of the esophagogastric junction.

【 授权许可】

   
2013 Zhang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Devesa SS, Blot WJ, Fraumeni JF Jr: Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998, 83:2049-2053.
• [2]Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991, 265:1287-1289.
• [3]Okabayashi T, Gotoda T, Kondo H, Inui T, Ono H, Saito D, Yoshida S, Sasako M, Shimoda T: Early carcinoma of the gastric cardia in Japan: is it different from that in the West? Cancer 2000, 89:2555-2559.
• [4]Hasegawa S, Yoshikawa T: Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies. Gastric Cancer 2010, 13:63-73.
• [5]UICC: Oesophagus including oesophagogastric junction. City: New York: Wiley-Blackwell; 2009:66-72. [TNM Classification of Malignant Tumours]
• [6]Siewert JR, Stein HJ: Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998, 85:1457-1459.
• [7]Bai JG, Lv Y, Dang CX: Adenocarcinoma of the esophagogastric junction in China according to Siewert's classification. Jpn J Clin Oncol 2006, 36:364-367.
• [8]Fang WL, Wu CW, Chen JH, Lo SS, Hsieh MC, Shen KH, Hsu WH, Li AF, Lui WY: Esophagogastric junction adenocarcinoma according to Siewert classification in Taiwan. Ann Surg Oncol 2009, 16:3237-3244.
• [9]Hosokawa Y, Kinoshita T, Konishi M, Takahashi S, Gotohda N, Kato Y, Daiko H, Nishimura M, Katsumata K, Sugiyama Y: Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan. Ann Surg Oncol 2011, 19(2):677-683.
• [10]American Joint Committee on Cancer: AJCC Cancer Staging Manual. 7th edition. City: New York: Springer-Verlag; 2010.
• [11]Kubo A, Corley DA: Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2006, 15:872-878.
• [12]Chow WH, Fraumeni JF Jr, Blot WJ, Vaughan TL, Stanford JL, Farrow DC, Risch HA, Dubrow R, Mayne ST, Gammon MD: Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998, 90:150-155.
• [13]Chow WH, Blaser MJ, Blot WJ, Gammon MD, Vaughan TL, Risch HA, Perez-Perez GI, Schoenberg JB, Stanford JL, Rotterdam H: An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998, 58:588.
• [14]Gertler R, Stein HJ, Loos M, Langer R, Friess H, Feith M: How to classify adenocarcinomas of the esophagogastric junction: as esophageal or gastric cancer? Am J Surg Pathol 2011, 35:1512-1522.
• [15]Siewert JR, Feith M, Stein HJ: Biologic and clinical variations of adenocarcinoma at the esophago–gastric junction: Relevance of a topographic‒anatomic subclassification. J Surg Oncol 2005, 90:139-146.
• [16]Von Rahden BHA, Stein HJ, Feith M, Becker K, Siewert JR: Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinomas of the esophagogastric junction. J Clin Oncol 2005, 23:874-879.
• [17]Reynolds JV, Ravi N, Muldoon C, Larkin JO, Rowley S, O’Byrne K, Hollywood D, O’Toole D: Differential pathologic variables and outcomes across the spectrum of adenocarcinoma of the esophagogastric junction. World J Surg 2010, 34:2821-2829.
• [18]Siewert JR, Feith M, Werner M, Stein HJ: Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 2000, 232:353.